Study backs Alterity tool for tracking MSA
Quality peer-reviewed publication highlights use of Alterity's MSA Atrophy Index developed to diagnose and track MSA disease progression
Tool helps pinpoint changes in brain over time, making it easier to detect disease progression and assess treatments
MSA Atrophy Index developed as part of Alterity's bioMUSE natural history study with Vanderbilt University Medical Center
The peer-reviewed study, published in peer-reviewed journal Annals of Clinical and Translational Neurology, highlights a new MRI-based measure called the MSA Atrophy Index (MSA-AI) – developed as part of Alterity Therapeutics' (ASX:ATH) bioMUSE natural history study.
Using artificial intelligence (AI), the tool helps pinpoint changes in the brain over time, making it easier to detect disease progression and assess how well treatments are working.
MSA-AI offers a standardised way to measure brain shrinkage in regions affected by the disease, regardless of the subtype.
This makes it a useful tool for both diagnosing patients earlier and improving how clinical trial participants are selected.
The study combined data from both early-stage and more advanced MSA patients, capturing a wide range of disease severity.
The approach has helped researchers confirm that the MSA-AI could reliably track changes in brain volume over time and differentiate MSA from other similar neurological conditions like Parkinson's disease and Lewy body dementia.
Importantly, lower MSA-AI scores were linked to more severe symptoms and greater disease progression over 12 months, highlighting the tool's potential value in future clinical trials and patient care.
About the bioMUSE study
Titled Biomarkers of Progression in Multiple System Atrophy (bioMUSE), the natural history study tracks the progression of individuals with MSA, a Parkinsonian disorder without an approved therapy.
The study was conducted in collaboration with Vanderbilt University Medical Center in the US under the direction of Daniel Claassen M.D, M.S, professor of neurology and principal investigator.
Alterity noted that natural history studies were important for characterising disease progression in selected patient populations.
Insights into early-stage MSA
The company said the study had provided rich data for optimising the design of its randomised ATH434-201 phase II clinical trial and had enrolled ~20 individuals with clinically probable or clinically established MSA.
The bioMUSE study continues to provide critical insights into early-stage MSA, helping select biomarkers and track disease progression in patients like those in its phase II trial.
'This research used state-of-the-art technology employed in the bioMUSE study that goes above and beyond traditional MRI methods for assessing brain volume in patients with MSA,' Alterity's US-based CEO Dr David Stamler said.
'Based on the creativity and technical skill of our colleagues at Vanderbilt University Medical Center, we now have superior tools for diagnosing MSA and tracking brain atrophy over time.
'Importantly, we observed that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of the disease.'
Stamler said the results underscore importance of using advanced neuroimaging methods and analytical tools in evaluating MSA, which Alterity implemented in its phase II clinical program.
'While previous MRI studies have reported brain volume reductions in MSA-affected brain regions, tracking these changes reliably has been challenging,' he said.
Stamler said development of the MSA Atrophy Index can enhance the understanding of MSA progression and provide support for using brain atrophy markers for evaluation of disease-modifying therapies.
'These tools offer potential applications in diagnosis, staging, and monitoring of disease severity, contributing to more personalised care in MSA,' he said.
'We look forward to leveraging this invaluable technology for patient selection and disease progression in our phase III clinical trial.'
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
18 hours ago
- News.com.au
Paralysed woman writes her name for the first time in 20 years after having Elon Musk Neuralink chip implant surgery
A woman paralysed since 2005 has written her name for the first time in two decades thanks to Elon Musk. Audrey Crews became the first woman in the world to undergo surgery earlier this month receiving Mr Musk's Neuralink chip implant, allowing her to control a computer with her mind. Ms Crews recently took to X to show the world how she was able to select a coloured cursor on screen and sign her name through telepathy. She showed off how she could also draw pictures, scroll with a mouse and use a keyboard just by thinking. 'I tried writing my name for the first time in 20 years. I'm working on it. Lol,' she said. 'I am the first woman in the world to do this.' Ms Crews was left a quadriplegic at age 16 following a car accident that left the vertebrae in her neck permanently damaged. By 2016, tech billionaire Musk co-founded Neuralink with expert in neuroscience in hopes of using AI tech to treat brain disorders. Three years later he revealed the N1 chip, which is placed on the brain to translate electrical signals into tasks. Ms Crews is just the ninth recipient. She underwent surgery at the University of Miami Health Centre where surgeons place over 100 threads, thinner than human hair into her motor cortex after drilling through her skull. The implant, roughly the size of a 10 cent coin, sends those signals to a linked computer or smartphone with Neuralink's software via Bluetooth, allowing patients with paralysis or neurological conditions to communicate digitally. 'Imagine your pointer finger is left click and the cursor is with your wrist, without physically doing it. Just a normal day using telepathy,' she said. Ms Crews has also started taking requests of what to draw next, recently sketching a cat, a sun and a tree after being asked by X users. She's also able to play simulation games testing her accuracy and speed by having her cursor track points on the screen as they change. Mr Musk even replied to a post about Ms Crews' story. 'She is controlling her computer just by thinking. Most people don't realise this is possible,' he said. While the technology won't allow her to regain movement of her limbs, the advancement has so far impressed Ms Crews who hopes to make the most of it by writing a book about her experiences. The chip is powered by a small battery that charges wirelessly. Asked if she ever imagined being able to communicate in such a way again, Ms Crews had one response: 'Not in all my wildest dreams, but the future is here.'
News.com.au
19 hours ago
- News.com.au
Concerning daycare images show children with their mouths taped shut in yoga exercise
A Sydney daycare centre has received a warning from the NSW Department of Education after concerning images emerged of children with their mouths covered with tape. The toddlers at Heritage House in Wahroonga, on Sydney's north shore, were participating in a breathing exercise as part of a yoga session last year. No injuries were reported from the exercise which was meant to be relaxing, but the Department launched an investigation into the matter after concerns were raised by a parent. 'While no children were harmed in this incident, it was an inappropriate activity that should not have taken place in an early learning centre,' a spokesperson from the NSW Early Childhood Education and Care Regulatory Authority told 'A thorough investigation was immediately conducted and a compliance action issued to the approved provider, which remains on their record.'  An external visitor was not running the yoga session, and the centre provided evidence to the Department that the mouth taping exercise has since been discontinued.  In a statement, Heritage House told the Sydney Morning Herald: 'It was a well-intentioned activity led by one of our educators, a yoga instructor.' 'We accept that the Department issued a warning and as a result we took steps to ensure that the activity was not repeated.' Photos of the activity were shared on the centre's parents app alongside a caption where an educator described the activity as 'unique'. 'The children gathered for a unique lesson combining breathwork, gentle yoga, and the tape-mouth technique. Guided to focus on nasal breathing, they playfully mimicked animals in yoga poses, learning to breathe deeply and calmly through their noses, fostering early mindfulness,' they wrote, according to SMH. A number of parents whose children attend the daycare threw their support behind the centre and its educators on Tuesday. One parent told 7News: 'They've always been very careful about the kids, their growth, their education, everything.' Another said: 'People are friendly, they seem engaged, kids are happy here.' Mouth taping, specifically for adults prone to mouth breathing while sleeping, has become a recent trend on TikTok but concerns have been raised about the dangers of restricting airflow.
The Australian
21 hours ago
- The Australian
EMVision to start two key studies
EMVision receives ethics approval for two studies that will advance prototype First Responder toward commercial production Studies designed to demonstrate First Responder brain scanner can fit into emergency workflows and collect valuable data in pre-hospital setting EMVision non-dilutive milestone payment received under Australian Stroke Alliance Project Agreement Special Report: EMVision Medical Devices has passed a major milestone with ethics approval granted for two key studies to advance its First Responder prototype portable device to detect stroke and traumatic brain injury (TBI). EMVision Medical Devices (ASX:EMV) said the Royal Flying Doctor Service (RFDS) pre-hospital aeromedical study and Melbourne Mobile Stroke Unit (MSU) study would advance its First Responder brain scanner toward commercial production. The studies are designed to demonstrate that the First Responder device can fit seamlessly into emergency workflows and collect valuable data in the pre-hospital setting. First Responder is EMVision's second device and designed to address significant unmet needs in stroke and TBI care by enabling earlier triage, transfer or treatment decisions at the scene. The device is being advanced in parallel with its emu bedside scanner to rapidly diagnose stroke at the point-of-care, which is currently in a pivotal trial to support US Food and Drug (FDA) de novo (new device) clearance. RFDS pre-hospital aeromedical study Ethics approval has been granted for a feasibility, usability and workflow implementation aeromedical study. The study is a collaboration of RFDS, South Australia Ambulance Service's emergency retrieval service MedStar, South Australia Health's Rural Support Services, the Royal Adelaide Hospital and the Australian Stroke Alliance. The study will evaluate the First Responder device's usability, reliability, functionality, workflow metrics and other tests as necessary to meet user and international regulatory requirements. EMVision said the study was on track to start recruitment this quarter, with study results expected to be reported next quarter. Melbourne Mobile Stroke Unit (MSU) Ethics approval has also been granted for a First Responder study during acute suspected stroke cases attended by the Melbourne Mobile Stroke Unit (MSU). EMVision said the study provided a unique opportunity to collaborate with the only MSUs in Australia and one of a few MSUs globally who participate in clinical research. The study aims to evaluate the use of First Responder during pre-hospital emergency response to acute suspected stroke patients, while gathering contemporaneous ground-truth MSU CT-scan data. This study is forecast to start later this quarter. Milestone payment of $400,000 from ASA In a further boost EMVision has reached a key development milestone under its project agreement with the Australian Stroke Alliance (ASA), supported by the Federal Government's Medical Research Future Fund (MRFF). The company has received a $400,000 non-dilutive payment for completing the Telemedicine and Road/Air Integration milestone, an achievement that advances its First Responder portable brain scanner program. EMVision's CEO Scott Kirkland said the company was delighted to report successful achievement of the important milestone, which brings together the power of its point-of-care neurodiagnostic capabilities with the reach of telehealth. 'This combination has the potential to transform patient workflows and outcomes, particularly in the pre-hospital setting,' he said. 'In the coming months, EMVision will be conducting several studies to progress development of its First Responder device, which will be integral to expediating its commercialisation via the FDA 510(k) regulatory pathway. 'We look forward to communicating the results of these studies to the market in due course.' First responder pathway to market entry Source:EMVision This article was developed in collaboration with EMVIsion, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
